指南与共识创伤与烧伤复苏、休克与脓毒症

勿忘冷沉淀:2019年联合创伤系统损伤控制复苏临床实践指南对死亡率的影响

Do not forget the cryoprecipitate: The impact of the 2019 Joint Trauma System Damage Control Resuscitation Clinical Practice Guideline on mortality.
指南 / 共识 · J Trauma Acute Care Surg · 2025-01-09
一句话结论在大量输血的平民创伤患者中,冷沉淀与浓缩红细胞高比例(≥1:1)与6小时、24小时及住院死亡率降低独立相关。

该研究基于创伤质量改进项目数据库(2013—2021年),纳入接受至少5 U浓缩红细胞和1 U新鲜冰冻血浆的成年创伤患者,按冷沉淀/浓缩红细胞比例分为高比例(≥1:1)、中比例(≥1:2至<1:1)和低比例(<1:2)三组,采用倾向评分加权风险调整模型估计治疗效果。共纳入49,301例患者,高、中、低比例组6小时未调整死亡率分别为11.8%、18.8%和21.3%。与低比例组相比,高比例组6小时死亡率调整比值比为0.52(95%CI 0.45-0.58),24小时为0.74(95%CI 0.67-0.82);中比例组6小时调整比值比为0.78(95%CI 0.70-0.87)。作者结论认为高冷沉淀比例与大量输血平民创伤患者24小时内死亡率降低独立相关,未来需前瞻性多中心随机试验验证。

要点

  • 在大量输血(≥5 U浓缩红细胞+1 U新鲜冰冻血浆)的成年创伤患者中,冷沉淀/浓缩红细胞≥1:1与6小时死亡率降低独立相关(aOR 0.52,95%CI 0.45-0.58)。
  • 冷沉淀/浓缩红细胞≥1:2至<1:1的中比例也与6小时死亡率降低相关(aOR 0.78,95%CI 0.70-0.87),但保护效应弱于高比例。
  • 高比例组24小时死亡率同样降低(aOR 0.74,95%CI 0.67-0.82),且敏感性分析调整新鲜冰冻血浆、血小板和全血后高、中比例对6小时、24小时及住院死亡率均有保护作用。
  • 2019年联合创伤系统损伤控制复苏指南推荐经验性1:1冷沉淀/浓缩红细胞,本研究为该推荐提供了平民创伤人群的观察性证据支持。

适用人群与场景

  • 成年创伤患者,来自创伤质量改进项目数据登记库(2013—2021年),接受至少5 U浓缩红细胞和1 U新鲜冰冻血浆(4小时内)。
  • 排除:30分钟内死亡、不可挽救的损伤模式、既往存在的凝血病、预先指示、转院患者及烧伤患者。

诊断标准与关键阈值

  • 冷沉淀/浓缩红细胞比例分组:高比例≥1:1;中比例≥1:2至<1:1;低比例<1:2。

研究设计与关键结果

  • 研究类型:基于创伤质量改进项目数据登记库(2013—2021年)的回顾性队列研究,采用倾向评分加权风险调整模型,按中心聚类。
  • 样本量:共49,301例患者,其中高比例组5,284例、中比例组3,630例、低比例组40,387例;平均年龄39岁,79%为男性,58%为钝性创伤,平均损伤严重度评分为29分。
  • 主要终点(6小时死亡率):未调整死亡率高比例组11.8%、中比例组18.8%、低比例组21.3%;高比例组 vs 低比例组 aOR 0.52(95%CI 0.45-0.58);中比例组 vs 低比例组 aOR 0.78(95%CI 0.70-0.87)。
  • 关键次要终点:24小时死亡率高比例组 vs 低比例组 aOR 0.74(95%CI 0.67-0.82);敏感性分析调整新鲜冰冻血浆、血小板和全血后,高、中比例对6小时、24小时及住院死亡率均有保护作用。

证据类型、等级与局限

  • 证据类型:回顾性队列研究(创伤质量改进项目数据登记库),证据等级:预后与流行病学,Level III。
  • 局限:作者指出未来需前瞻性多中心随机试验验证。

对床旁实践的改变

  • 对于接受大量输血(至少5 U浓缩红细胞和1 U新鲜冰冻血浆)的成年创伤患者,作者认为高冷沉淀/浓缩红细胞比例(≥1:1)与6小时、24小时死亡率降低独立相关;该结论来自观察性研究,作者建议未来开展前瞻性多中心随机试验。

指南或共识出处

  • 联合创伤系统(Joint Trauma System)2019年损伤控制复苏临床实践指南推荐经验性1:1冷沉淀/浓缩红细胞。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The benefit of transfusion of fresh frozen plasma (FFP) and platelets in a 1:1 ratio with packed red blood cells (PRBCs) is well established; however, the benefit of a particular ratio of cryoprecipitate to PRBC is not. The Joint Trauma System updated its 2019 Damage Control Resuscitation Guideline by recommending empiric 1:1 cryoprecipitate/PRBCs. We hypothesized that patients receiving product within the cryoprecipitate/PRBC guideline range (high ratio) would have an associated reduction in mortality.

METHODS: We included adult patients in the Trauma Quality Improvement Program data registry (2013-2021) who received at least 5 U of PRBCs and 1 U of FFP within 4 hours. Death within 30 minutes, nonsurvivable injury patterns, preexisting coagulopathy, advanced directives, transfers, and burns were excluded. Patients were partitioned into high (≥1:1), medium (≥1:2 to <1:1), and low (<1:2) cryoprecipitate/PRBC ratios. Treatment effects were estimated with propensity score-weighted risk adjustment models, clustering by center. The primary outcome was 6-hour mortality. Secondary outcomes included 24-hour and inpatient mortality. Adjusting for FFP, platelets, and whole blood was included as a sensitivity analysis.

RESULTS: A total of 49,301 patients (high, 5,284; medium, 3,630; low, 40,387) were included. The mean age was 39, 79% were male, 58% suffered blunt trauma, and the mean Injury Severity Score was 29. Unadjusted 6-hour mortality was 11.8%, 18.8%, and 21.3% for high, medium, and low ratios. High ratio was protective as compared with low at 6 hour (adjusted odds ratio [aOR], 0.52; 95% confidence interval [CI], 0.45-0.58) and 24 hours (aOR, 0.74; 95% CI, 0.67-0.82), and medium ratio was protective as compared with low ratio at 6 hours (aOR, 0.78; 95% CI, 0.70-0.87). Blood product sensitivity analysis demonstrated that high and medium ratios were protective of 6-hour, 24-hour, and inpatient mortality.

CONCLUSION: High cryoprecipitate ratios were independently associated with decreased mortality in massively transfused civilian trauma patients during the first 24 hours. Future prospective multicenter randomized trials are warranted.

LEVEL OF EVIDENCE: Prognostic and Epidemiological; Level III.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Hynes AM, Cannon JW, Yan R, et al. Do not forget the cryoprecipitate: The impact of the 2019 Joint Trauma System Damage Control Resuscitation Clinical Practice Guideline on mortality. J Trauma Acute Care Surg. 2025. PMID: 41589734. doi:10.1097/TA.0000000000004862

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。